A double‐blind dose‐escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis
- 11 January 2005
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 21 (2), 133-140
- https://doi.org/10.1111/j.1365-2036.2005.02312.x
Abstract
Mesalazine as the treatment standard for ulcerative colitis can be applied in different galenical preparations. A novel formulation of mesalazine pellets with delayed and prolonged release characteristics was compared with conventional Eudragit L-coated tablets. Furthermore, the effect of mesalazine dose escalation on nonresponders was evaluated in both treatment groups. A total of 233 patients with mild to moderately active ulcerative colitis were randomized to receive either mesalazine (1.5 g/day in three doses) as pellets (n = 115) or tablets (n = 118) for 8 weeks. At insufficient response, the dose was increased to 3.0 g. The clinical remission rate (clinical activity index < or = 4) for pellets was 67% vs. 68% for tablets which statistically proved to be not inferior (significance level alpha = 2.5%). In patients without dose increase, the remission rate was 47% (pellets) vs. 42% (tablets). Endoscopic improvement was observed in 80% (pellets) vs. 83% (tablets), and histological improvement in 48% (pellets) vs. 52% (tablets) of patients. Mesalazine pellets are as effective as tablets in the treatment of mild to moderately active ulcerative colitis. Dose escalation to 3.0 g/day is a valid option for nonresponders to a starting dose of 1.5 g/day.Keywords
This publication has 21 references indexed in Scilit:
- Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitisGastroenterology, 2000
- Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitisAlimentary Pharmacology & Therapeutics, 1998
- Interaction of 5-aminosalicylic acid with nitric oxide on rat aortic strips and human plateletsEuropean Journal of Pharmacology, 1995
- Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation.Gut, 1992
- Einfluß der Nahrungsaufnahme auf die Magenentleerung magensaftresistenter Tabletten und Kapseln*Deutsche Medizinische Wochenschrift (1946), 1992
- Scavenging effect of 5-aminosalicylic acid on neutrophil-derived oxidants: Possible contribution to the mechanism of action in inflammatory bowel diseaseBiochemical Pharmacology, 1991
- Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis.Gut, 1990
- Mesalazine A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Chronic Inflammatory Bowel DiseaseDrugs, 1989
- Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.BMJ, 1989
- Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug dispositionJournal of Gastroenterology and Hepatology, 1986